Quick Takeaways
- This page summarizes Isaac Manke's Form 4 filing for Q32 Bio Inc. (QTTB).
- 7 reported transactions and 7 derivative rows are listed below.
- Filing timestamp: 27 Feb 2025, 06:05.
Isaac Manke - 15 Jan 2025 Form 4 Insider Report for Q32 Bio Inc. (QTTB)
- Role
- Director
- Signature
- /s/ Eric Bell, Attorney-in-Fact
- Issuer symbol
- QTTB
- Transactions as of
- 15 Jan 2025
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 27 Feb 2025, 06:05:43 UTC
- Previous filing
- 08 Oct 2024
- Next filing
- 02 Apr 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Isaac Manke filed Form 4 for Q32 Bio Inc. (QTTB) on 27 Feb 2025."
What Changed
- Previous filing in this sequence was filed on 08 Oct 2024.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | QTTB | Stock Option (Right to Buy) | Disposed to Issuer | $0 | -12,767 | -100% | $0.000000 | 0 | 24 Feb 2025 | Common Stock | 12,767 | $16.82 | Direct | F1, F2 |
| transaction | QTTB | Stock Option (Right to Buy) | Award | $0 | +12,767 | $0.000000 | 12,767 | 24 Feb 2025 | Common Stock | 12,767 | $2.54 | Direct | F1, F2, F3 | |
| transaction | QTTB | Stock Option (Right to Buy) | Disposed to Issuer | $0 | -2,627 | -100% | $0.000000 | 0 | 24 Feb 2025 | Common Stock | 2,627 | $18.00 | Direct | F1, F2 |
| transaction | QTTB | Stock Option (Right to Buy) | Award | $0 | +2,627 | $0.000000 | 2,627 | 24 Feb 2025 | Common Stock | 2,627 | $2.54 | Direct | F1, F2, F3 | |
| transaction | QTTB | Stock Option (Right to Buy) | Award | $0 | +19,008 | $0.000000 | 19,008 | 15 Jan 2025 | Common Stock | 19,008 | $3.20 | Direct | F4 | |
| transaction | QTTB | Stock Option (Right to Buy) | Disposed to Issuer | $0 | +19,008 | $0.000000 | 0 | 24 Feb 2025 | Common Stock | 19,008 | $3.20 | Direct | F1, F2 | |
| transaction | QTTB | Stock Option (Right to Buy) | Award | $0 | +19,008 | $0.000000 | 19,008 | 24 Feb 2025 | Common Stock | 19,008 | $2.53 | Direct | F1, F2, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. |
| F2 | This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| F3 | The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. |
| F4 | This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Plan and pursuant to the Issuer's non-employee director compensation policy. This option represents the Reporting Person's election to receive stock options in lieu of cash retainer fees Due to administrative oversight this option award initially was not reported. |